AbbVie
ABBV
#29
Rank
NZ$754.37 B
Marketcap
NZ$426.97
Share price
-2.51%
Change (1 day)
33.69%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$3.51

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$3.50. In 2025 the company made an earnings per share (EPS) of NZ$4.07 a decrease over its 2024 EPS that were of NZ$4.12.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$3.51-13.74%
2025NZ$4.07-1.26%
2024NZ$4.12-11.86%
2023NZ$4.68-58.95%
2022NZ$11.392.49%
2021NZ$11.11121.58%
2020NZ$5.02-44.7%
2019NZ$9.0745.84%
2018NZ$6.229.72%
2017NZ$5.67-9.54%
2016NZ$6.2716.28%
2015NZ$5.39184.1%
2014NZ$1.90-57.15%
2013NZ$4.43

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.23-36.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$48.03 1,272.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.64 603.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$15.91 354.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$12.63 260.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.06 73.08%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$11.83 237.90%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$6.61 88.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$11.42 226.23%๐Ÿ‡บ๐Ÿ‡ธ USA